RARE as reported
Ultragenyx Pharmaceutical Inc. reported $717M of revenue over the trailing twelve months, +18% on the year before. 9 reported series are charted on this page, each one as filed.
$717M
Revenue, trailing twelve months · to Q2 2026 · +18% against the twelve months before
- Net Income
- −$586M
Net Income · +10.0% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$489M
Free Cash Flow · +14% year on year · trailing twelve months to Q2 2026
- Op Margin
- −80%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $717M | +18% | Q2 2026 |
| Net Income | −$586M | +10.0% | Q2 2026 |
| EPS | −$5.83 | +5.6% | Q2 2026 |
| Gross Margin | 97% | n/a | Q2 2019 · 28 quarters behind |
| Op Margin | −80% | n/a | Q2 2026 |
| Net Margin | −88% | n/a | Q2 2026 |
| ROE | −1288% | n/a | Q2 2026 |
| ROA | −45% | n/a | Q2 2026 |
| Free Cash Flow | −$489M | +14% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Ultragenyx Pharmaceutical Inc. (RARE) - Revenue & ProfitRevenue & ProfitUltragenyx Pharmaceutical Inc. (RARE)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com